November 21, 2018 / 4:42 PM / 25 days ago

BRIEF-Genentech Says FDA Approves Venclexta in Newly-Diagnosed AML

Nov 21 (Reuters) - Genentech:

* GENENTECH - FDA GRANTED ACCELERATED APPROVAL TO VENCLEXTA, IN COMBINATION WITH A HYPOMETHYLATING AGENT, OR LOW-DOSE CYTARABINE IN NEWLY-DIAGNOSED AML Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below